Home › Melanoma › California › Los Angeles
Melanoma clinical trials in Los Angeles, CA
34 studies for Melanoma are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- and 1 more
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RecruitingPhase 3
- University of California Los Angeles, Los Angeles
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RecruitingPhase 3
- USC Norris Comprehensive Cancer Center, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- University of Southern California, Los Angeles
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RecruitingPhase 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingPhase 1/2
- START Los Angeles, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RecruitingPhase 1/2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Children's Hospital Los Angeles, Los Angeles
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
RecruitingPhase 1
- START Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
The Multicentre Selective Lymphadenectomy Trial - 3
Recruiting
- Cedars-Sinai Medical Centre, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RecruitingPhase 1/2
- UCLA Medical Center, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Jules Stein Eye Institute, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
- Oncology Institute for Hope and Innovation, Los Angeles
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RecruitingPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
RecruitingPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- The Angeles Clinic and Research Institute, Los Angeles
- University of California Los Angeles, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RecruitingPhase 2
- The Angeles Clinic at Cedars Sinai, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- UCLA Health, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
- Los Angeles General Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
- and 2 more
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Nashville, TN33 studies
- Pittsburgh, PA31 studies
- Boston, MA26 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Atlanta, GA21 studies
- Durham, NC21 studies
- St. Louis, MO21 studies
- Columbus, OH21 studies
- Salt Lake City, UT21 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)73 studies
- Breast Cancer72 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Triple-Negative Breast Cancer27 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.